New safety concern related to antipsychotic treatment

Dec 01, 2009

Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia. In the current issue of Biological Psychiatry, published by Elsevier, researchers discuss this cluster of metabolic side effects and how it may contribute to the risk for diabetes, hypertension, and other medical disorders associated with heart disease. This is of particular concern because there is a higher cardiovascular mortality among the severely mentally ill compared to the general population.

Researchers already know that differences exist between antipsychotics in their effect on clinical measures associated with cardiovascular risk, namely weight, lipids and glucose. Systemic inflammation has recently emerged as an important marker of cardiovascular risk, but the effects of on inflammatory markers in the blood have not been extensively studied until now.

Using data from the multi-center CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) study, funded by the National Institute of Mental Health, Jonathan Meyer and colleagues examined the impact of multiple antipsychotic therapies on changes in systemic inflammation. Their findings provide evidence that antipsychotic medications, particularly olanzapine (Zyprexa®, Eli Lilly and Co.) and quetiapine (Seroquel®, AstraZeneca), increase the levels of inflammation markers.

The markers implicated include C-reactive protein, E-selectin, and intercellular adhesion molecular-1 (ICAM-1). Increased levels of C-reactive protein in particular are associated with increased risk for the development or progression of many illnesses including heart disease, and stroke.

"This analysis provides the most compelling evidence to date that differences in antipsychotic metabolic liability are also seen with markers of ," explained Dr. Meyer. "It also provides an impetus for monitoring markers in antipsychotic treated patients."

Dr. John Krystal, the Editor of , which is publishing this report, commented, "Doctors always try to balance the benefits and the risks associated with medications when making the decision to prescribe a particular medication to a particular patient. The more information that we have regarding the consequences of prescribing particular medications, the better the prescribing decisions can be." Although this report does not provide any direct evidence linking the antipsychotic medications to these disorders, he added that "it is helpful to know that antipsychotic medications may contribute to inflammatory processes in the body and that these medications differ somewhat in producing this effect."

More information: The article is " in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study" by Jonathan M. Meyer, et al. The article appears in Biological Psychiatry, Volume 66, Issue 11 (December 1, 2009), published by Elsevier.

Source: Elsevier

Explore further: Early exposure to antidepressants affects adult anxiety and serotonin transmission

add to favorites email to friend print save as pdf

Related Stories

Combating weight gain caused by antipsychotic treatments

Mar 26, 2009

Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems ...

Recommended for you

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

DanielHaszard
not rated yet Dec 02, 2009



Eli Lilly sells a drug (Zyprexa) that can cause diabetes and then turn a profit on the drugs that treat the condition that they may have caused in the first place!

Eli Lilly has made $38 billion on Zyprexa and it was way oversold and caused diabetes and in some cases sudden death.
Eli Lilly has received a huge criminal fine over their Zyprexa cash cow,add it all up comes to $4.6 billion, in Zyprexa settlements,fines,litigation.

Did you know that Lilly made $ billions last year on diabetic meds, Actos,Humulin and Byetta?

They sell a drug that can cause diabetes and then turn a profit on the drugs that treat the condition that they may have caused in the first place!

----
Daniel Haszard Zyprexa whistle-blower zyprexa-victims.com



Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.